MediciNova Price Sales Ratio from 2010 to 2024

MNOV Stock  USD 2.17  0.01  0.46%   
MediciNova Price Sales Ratio yearly trend continues to be fairly stable with very little volatility. Price Sales Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, MediciNova Price Sales Ratio regression line of quarterly data had mean square error of  341.10 and geometric mean of  28.86. View All Fundamentals
 
Price Sales Ratio  
First Reported
2010-12-31
Previous Quarter
84.6
Current Value
107.43
Quarterly Volatility
27.72672087
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MediciNova financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MediciNova's main balance sheet or income statement drivers, such as Interest Expense of 679.1 K, Other Operating Expenses of 14.5 M or Research Development of 7.9 M, as well as many indicators such as Price To Sales Ratio of 107, Dividend Yield of 0.0 or PTB Ratio of 1.63. MediciNova financial statements analysis is a perfect complement when working with MediciNova Valuation or Volatility modules.
  
Check out the analysis of MediciNova Correlation against competitors.
For more information on how to buy MediciNova Stock please use our How to Invest in MediciNova guide.

Latest MediciNova's Price Sales Ratio Growth Pattern

Below is the plot of the Price Sales Ratio of MediciNova over the last few years. It is MediciNova's Price Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MediciNova's overall financial position and show how it may be relating to other accounts over time.
Price Sales Ratio10 Years Trend
Slightly volatile
   Price Sales Ratio   
       Timeline  

MediciNova Price Sales Ratio Regression Statistics

Arithmetic Mean40.18
Geometric Mean28.86
Coefficient Of Variation69.01
Mean Deviation19.34
Median32.26
Standard Deviation27.73
Sample Variance768.77
Range106
R-Value0.77
Mean Square Error341.10
R-Squared0.59
Significance0.0009
Slope4.75
Total Sum of Squares10,763

MediciNova Price Sales Ratio History

2024 107.43
2023 84.6
2022 73.57
2014 32.26
2013 7.38
2011 35.27
2010 1.12

About MediciNova Financial Statements

MediciNova investors use historical fundamental indicators, such as MediciNova's Price Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MediciNova. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Sales Ratio 84.60  107.43 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MediciNova Stock Analysis

When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.